Recombinant Mouse HVEM/TNFRSF14 Protein (His & Fc Tag)(Active)

according to manual

A DNA sequence encoding the extracellular domain (Met 1-Gln 206) of mouse HVEM (NP_849262.1) precursor was fused with C-terminal His-tagged Fc region of human IgG1 at the C-terminus.

C-His-Fc

This product is provided as lyophilized powder which is shipped with ice packs.

< 1.0 EU per ug of the protein as determined by the LAL method.

46.4 kDa

Lyophilized from sterile PBS, pH 7.4

Herpesvirus entry mediator (HVEM), also referred to as TNFRSF14, TR2 (TNF receptor-like molecule) and ATAR (another TRAF-associated receptor), is a member of type I transmembrane protein belonging to the TNF-receptor superfamily. It is expressed on many immune cells, including T and B cells, NK cells, monocytes, and neutrophils. Two TNF superfamily ligands lymphotoxin α (TNF-β ) and LIGHT (TNFSF14) are identified as cellular ligands for HVEM and initiate the positive signaling. However, recent studies have revealed that HVEM is also involved in the unique inhibitory signaling pathway for T cells through activating tyrosine phosphorylation of the immunoreceptor tyrosine-based inhibitory motif (ITIM) in B and T lymphocyte attenuator (BTLA). HVEM provides a stimulatory signal following engagement with LIGHT (TNFSF14) on T cells. In contrast, it can also provide an inhibitory signal to T cells when it binds the B and T lymphocyte attenuator (BTLA), a ligand member of the Immunoglobulin (Ig) superfamily. Thus, HVEM may be viewed as a molecular switch, capable of facilitating both stimulatory and inhibitory cosignaling in T cells. Substantial evidence from both human disease and from experimental mouse models has indicated that dysregulation of the LIGHT-HVEM-BTLA cosignaling pathway can cause inflammation in the lung and in mucosal tissues.Immune CheckpointImmune Checkpoint Detection: Antibodies      Immune Checkpoint Detection: ELISA AntibodiesImmune Checkpoint ProteinsImmune Checkpoint Targets      Co-inhibitory Immune Checkpoint Targets Immunotherapy      Cancer Immunotherapy      Targeted Therapy